QCM Cayman’s Vertex Pharmaceuticals VRTX Stock Holding History

QCM Cayman’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-872	Closed	-$252K	–	81
2022 Q4	$252K	Buy	+872	New	+$266K	3.87%	11
2021 Q3	–	Sell	-1,264	Closed	-$255K	–	180
2021 Q2	$255K	Buy	+1,264	New	+$264K	0.66%	65
2015 Q1	–	Sell	-2,334	Closed	-$277K	–	277
2014 Q4	$277K	Buy	+2,334	New	+$263K	0.12%	135
2014 Q2	–	Sell	-4,183	Closed	-$296K	–	349
2014 Q1	$296K	Buy	+4,183	New	+$331K	0.07%	179

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM Cayman's VRTX Position: Q1 2023 in Review

QCM Cayman sold out of Vertex Pharmaceuticals (VRTX) in Q1 2023, closing a stake of 872 shares — an estimated $252K sold.

QCM Cayman first reported a position in VRTX in Q1 2014 and held it in 4 quarters. The position peaked at $296K in Q1 2014. 1,207 funds tracked by Wall St. Rank hold VRTX as of Q1 2023.

QCM Cayman reported no remaining Vertex Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
QCM Cayman sold 872 Vertex Pharmaceuticals shares in Q1 2023, an estimated $252K.
QCM Cayman first reported a position in Vertex Pharmaceuticals in Q1 2014 and held it in 4 quarters.
QCM Cayman's Vertex Pharmaceuticals position peaked at $296K in Q1 2014.
1,207 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2023.

Based on QCM Cayman's 13F filing for Q1 2023, filed 24 Apr 2023.